PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

Blood

Volumn 117, Issue 26, 2011, Pages 7090-7098

  Kleppe, Maria ^a,b   Soulier, Jean ^c   Asnafi, Vahid ^d   Mentens, Nicole ^a,b   Hornakova, Tekla ^e,f   Knoops, Laurent ^e,f,g   Constantinescu, Stefan ^e,f,g   Sigaux, François ^c   Meijerink, Jules P ^h   Vandenberghe, Peter ^b   Tartaglia, Marco ⁱ   Foa, Robin ^j   Macintyre, Elizabeth ^d   Haferlach, Torsten ^k   Cools, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c SAINT LOUIS HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^f DE DUVE INSTITUTE   (Belgium)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h SOPHIA CHILDREN S HOSPITAL   (Netherlands)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k MLL MUNICH LEUKEMIA LABORATORY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3; JANUS KINASE 1; JANUS KINASE 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; ONCOPROTEIN; PROTEIN ABL1; PROTEIN NUP214; PROTEIN TLX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOID CELL; MALE; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 79959826613     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-314286     Document Type: Article

References (26)

1. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica. 2005;90(8):1116-1127. (Pubitemid 41323512)
2. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (TALL). Blood. 2005;106(1):274-286. (Pubitemid 40967203)
3. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87. (Pubitemid 41039178)
4. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114(3):647-650.
5. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010;115(14):2845-2851.
6. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271. (Pubitemid 39336870)
7. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113(17):3918-3924.
8. Wright DD, Sefton BM, Kamps MP. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol. 1994;14(4):2429-2437. (Pubitemid 24108225)
9. Asnafi V, Le Noir S, Lhermitte L, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol. 2010;148(1):178-179.
10. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205(4):751-758. (Pubitemid 351549874)
11. Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49(4):299-308.
12. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84(12):4038-4044.
13. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36(10):1084-1089. (Pubitemid 41184470)
14. Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14(12):3716-3721.
15. Kleppe M, Lahortiga I, El Chaar T, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(6):530-535.
16. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol. 2002;12(6):446-453. (Pubitemid 34248890)
17. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol. 2002;22(16):5662- 5668.
18. Lu X, Chen J, Sasmono RT, et al. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol Cell Biol. 2007;27(6):2166-2179. (Pubitemid 46418473)
19. Hornakova T, Chiaretti S, Lemaire MM, et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood. 2010;115(16):3287-3295.
20. De Keersmaecker K, Graux C, Odero MD, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105(12):4849-4852. (Pubitemid 40807313)
21. Kleppe M, Mentens N, Tousseyn T, Wlodarska I, Cools J. MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context. Haematologica. 2011;96(5):779-783.
22. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol. 2007;19(1):55-60. (Pubitemid 44885601)
23. Stuible M, Doody KM, Tremblay ML. PTP1B and TC-PTP: regulators of transformation and tumorigenesis. Cancer Metastasis Rev. 2008;27(2):215-230.
24. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178. (Pubitemid 43076714)
25. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22(1):23-30.
26. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010;13(6):394-403.